Rhamnogalacturonan-I (carrot RG-I) and gut microbiota
What 2 graded rows on rhamnogalacturonan-i (carrot rg-i) agree on for gut microbiota, and where they differ. Counted side by side, never averaged.
Consensus finder Rows from the Rhamnogalacturonan-I (carrot RG-I) page, reviewed Oct 21, 2026 How it decides
What the rows agree on
Each block and row is one graded row from the Rhamnogalacturonan-I (carrot RG-I) page, with its PubMed record.
Your question
Rhamnogalacturonan-I (carrot RG-I) and gut microbiota
2 rows · 200 peopleSplit. 1 row found an improvement and 1 had mixed results.
- DGrade D× 2
- Rows
- 2
- Trials
- 2
- People
- 200
What the rows share
From the rowsThe best-graded row, grade D, is a randomized trial of 146 people (2024) and reported mixed results.
The rows run from 54 to 146 people, published from 2024 to 2025: 2 single studies.
The rows
1 improved · 1 mixed- DGrade DFaecal Bifidobacterium, immune cell activation and stool consistency · Improved
RCT · n 54 · 2025 · Healthy adults aged 18–70 (Sweden)
500 mg/day · 4 weeks
Faecal Bifidobacterium rose, peaking at week 3; isobutyric acid rose but other short-chain fatty acids did not; more circulating dendritic cells carried activation markers; stool consistency improved slightly.
Row on the Rhamnogalacturonan-I (carrot RG-I) page · PubMed 41011488 (opens PubMed)
- DGrade DGut microbiota composition (same challenge trial) · Mixed
RCT · n 146 · 2024 · Healthy adults in the rhinovirus challenge trial (placebo 46, 0.3 g/day 49, 1.5 g/day 51)
0.3 g/day or 1.5 g/day · 8 weeks
Overall microbiota composition did not change, but Bifidobacterium (mainly B. adolescentis and B. longum) increased at both doses, and microbiota became more stable. Symptom severity did not correlate directly with the microbial changes.
Row on the Rhamnogalacturonan-I (carrot RG-I) page · PubMed 38593705 (opens PubMed)